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Abstract
Background: Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in adults even in
developed countries. Several lifestyle factors and comorbidities have been linked to an increased risk, although their
prevalence has not been well documented in the primary care setting. The aim of this study is to assess the
incidence, risk factor and comorbid conditions distribution of CAP in adults in primary care in Spain.
Methods: Retrospective observational study in adults (>18 years-old) with CAP diagnosed and attended at primary
care in Spain between 2009 and 2013, using the Computerized Database for Pharmacoepidemiological Studies in
Primary Care (BIFAP).
Results: Twenty-eight thousand four hundred thirteen patient records were retrieved and analyzed. Mean age
(standard deviation): 60.5 (20.3) years, 51.7 % males. Global incidence of CAP in adults was estimated at 4.63
per 1000 persons/year. CAP incidence increased progressively with age, ranging from a 1.98 at 18–20 years of
age to 23.74 in patients over 90 years of age. According to sex, global CAP incidence was slightly higher in
males (5.04) than females (4.26); CAP incidence from 18 to 65 year-olds up was comparable between males
(range: 2.18–5.75) and females (range: 1.47–5.21), whereas from 65 years of age, CAP incidence was noticeable
higher in males (range: 7.06–36.93) than in females (range: 5.43–19.62). Average prevalence of risk factors was
71.3 %, which increased with age, doubling the risk in males by the age of 75 (females 20 % vs males 40 %).
From 55 years of age, at least one risk factor was identified in 85.7 % of cases: one risk factor (23.8 %), two
risk factors (23.4 %), three or more risk factors (38.5 %). Major risk factors were: metabolic disease (27.4 %),
cardiovascular disease (17.8 %) and diabetes (15.5 %).
(Continued on next page)
* Correspondence: federico.martinon.torres@sergas.es
†Equal contributors
1Translational Pediatrics and Infectious Diseases Section, Pediatrics
Department, Hospital Clínico Universitario de Santiago de Compostela,
Travesía da Choupana, s/n, 15706 Santiago de Compostela, Spain
2Genetics, Vaccines, Infections and Pediatrics Research Group (GENVIP),
Healthcare Research Institute of Santiago de Compostela, Santiago de
Compostela, Spain
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rivero-Calle et al. BMC Infectious Diseases  (2016) 16:645 
DOI 10.1186/s12879-016-1974-4
(Continued from previous page)
Conclusions: The annual incidence of CAP in primary care adults in Spain is high, comparable between
males and females up to 65 years of age, but clearly increasing in males from that age. CAP risk increases
with age and doubles in males older than 75 years. The majority of CAP cases in patients over 55 years of
age is associated to at least one risk factor. The main risk factors associated were metabolic disease,
cardiovascular disease, and diabetes.
Keywords: Community-acquired pneumonia, Vaccine-preventable diseases, Risk factors, Incidence, Antibiotics,
Primary care
Background
Community-acquired pneumonia (CAP) is a major cause
of morbidity and mortality in adults even in developed
countries [1–3]. CAP leads to high rates of hospitalization,
particularly in the elderly, and belongs to the top 5 causes
of death globally [4]. Depending on the geographic area
analyzed, the estimated annual incidence ranges between
1.6 and 12 cases per 1000 population [5–9].
Several lifestyle factors have been associated with an
increased risk of CAP including smoking, alcohol abuse,
being underweight, having regular contact with children,
and poor dental hygiene, among others [10–12]. Also
the presence of comorbid conditions, including chronic
respiratory and cardiovascular diseases, cerebrovascular
disease, Parkinson’s disease, epilepsy, dementia, dyspha-
gia, HIV or chronic renal or liver disease have been
linked to an increased risk of CAP [10–12].
The burden of pneumonia is of considerable import-
ance. However, the prevalence of different lifestyle risk
factors and comorbidities in patients seeking medical as-
sistance at primary care level because of pneumonia has
not been well documented. This study aims to describe
the prevalence of different lifestyle risk factors and co-
morbidities in patients with CAP at primary care in
Spain during a 5 year period (2009–2013).
Methods
An observational retrospective study was designed to
evaluate the incidence of CAP and the prevalence and
distribution of risk factors and comorbidities in adults in
primary care in Spain, attended between 2009 and 2013.
Data collection was performed using the Computer-
ized Database for Pharmacoepidemiological Studies in
Primary Care (BIFAP). BIFAP is a computerized data-
base aggregating information provided by 2692 general
practitioners and pediatricians working in the Spanish
National Health Service. The ownership of this database
is public, and its sole purpose is to enable epidemio-
logical studies, and in particular pharmacoepidemiologi-
cal studies. The information related to these patients is
kept completely confidential and strictly compliant with
current Spanish and European legislation. Collaboration
by general practitioners in BIFAP is personal, individual
and voluntary. BIFAP is sponsored by three leading
Spanish medical societies in primary care: Sociedad
Española de Medicina Familiar y Comunitaria (SEM-
FYC), Sociedad Española de Médicos de Atención
Primaria (SEMERGEN) and Asociación Española de
Pediatría de Atención Primaria (AEPAP). The BIFAP
database includes clinical and prescription data for
around 4.8 million patients.
Eligible study participants were Spanish adults 18 years
of age or older, of both sexes, diagnosed of the first epi-
sode of CAP between January 2009 and December 2013.
Patients had to have been recorded with the doctor for
1 year at least. Patients with previous diagnoses of pneu-
monia or nosocomial pneumonia were excluded.
All patients were identified when a first register of pneu-
monia during the study period was detected in their med-
ical history. Patients with a potential diagnosis of
pneumonia were selected through a computerized algo-
rithm that identified them through process codes (CIAP
R81), or through the occurrence of the word “pneumonia”
in the free text history. Cases were included when there
was a radiological diagnosis and/or where the diagnosis
was reported by another professional in a medical record.
Doubtful cases, which involved presumptive diagnosis not
confirmed by additional tests, or those where information
in the clinical history was insufficient, were excluded.
Different lifestyle risk factors and comorbidities as-
sociated to the first register of pneumonia were also
retrieved and analyzed (Additional file 1). Comorbidi-
ties in BIFAP database are codified according to the
Spanish version of the International Classification of
Diseases, 9th Revision, Clinical Modification (Modifi-
cación Clínica Clasificación Internacional de Enferme-
dades; CIE-9-MC) and/or the Spanish version of the
International Classification of Primary Care (CIAP-2/
ICPC-2 PLUS) (Additional file 1).
Statistical analysis
Data were presented as mean (standard deviation) or
frequency (percentage) as appropriate. We carried out a
descriptive analysis of the first episodes of CAP, preva-
lence of the different lifestyle risk factors and comorbidi-
ties stratified by age and gender. The relationship was
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tested using a binary logistic model. We performed all
the analyses using R Software, Version 3.0.2.
Results
A total of 2,332,622 adult patients (18 years of age or
older) were included in the study cohort. 28,413 subjects
with a mean age (standard deviation) of 60.5 (20.3) years
had a first episode of pneumonia during the study period
(Table 1).
Incidence of CAP
Global incidence of CAP in adults was estimated at 4.63
per 1000 persons/year (Table 2). CAP incidence in-
creased progressively with age, ranging from a 1.98 at
18–20 years of age to 23.74 in patients over 90 years of
age (Table 2). According to gender, global CAP inci-
dence was slightly higher in males (5.04) than females
(4.26) (Table 2). CAP incidence from 18 to 65 year-olds
up was comparable between males (range: 2.18–5.75)
and females (range: 1.47–5.21), whereas from 65 years of
age, CAP incidence was noticeable higher in males
(range: 7.06–36.93) than in females (range: 5.43–19.62)
(Table 2).
Risk factors for CAP
Overall, the main risk factors detected were: metabolic
disease (27.4 %), cardiovascular disease (17.8 %), diabetes
(15.5 %), depression (14.8 %), smoking (13.0 %), anemia
(12.3 %), poor dental hygiene (11.8 %), chronic obstruct-
ive pulmonary disease (COPD) (10.8 %) and cerebrovas-
cular disease (7.8 %) (Figs. 1 and 2).
The main risk factors according to age were (Fig. 1):
between 18 and 25 years: 9.1 % poor dental hygiene,
8.0 % smoking, 7.8 % asthma, 5.7 % anemia and 3.6 %
low weight; between 25 and 40 years: smoking 13.5 %,
10.0 % poor dental hygiene, 7.1 % anemia, 6.6 % depres-
sion, 5.9 % metabolic disease and 4.9 % asthma; between
40 and 55 years: smoking 20.9 %, metabolic disease
17.7 %, depression 12.0 %, poor dental hygiene 11.5 %,
and anemia 9 %; between 55 and 70 years: 40.4 % meta-
bolic disease, smoking 18.3 %, 17.9 % diabetes, 17.0 %
depression, 15.5 % cardiovascular disease, 14.3 %, poor
dental hygiene and 11.7 % COPD; between 70 and
85 years: 41.5 % metabolic disease, 33.0 % cardiovascular
disease, 28.9 % diabetes, COPD 21.5 %, 19.4 % depres-
sion, anemia 16.7 % and 14.4 % cerebrovascular disease;
over 85 years: 39.3 % cardiovascular disease, 27.5 %
metabolic disease, 25.6 % anemia, 23.5 % cerebrovascular
disease, 22.6 % diabetes, 20.6 % depression, 18.6 %
dementia and 16.1 % COPD.
The main risk factors according to gender were (Fig. 2):
women: metabolic disease (26.9 %), depression (20.0 %),
anemia (15.8 %) and cardiovascular disease (15.0 %);
men: metabolic disease (27.8 %), cardiovascular disease
(20.5 %), diabetes (17.9 %) and smoking (15.5 %). Over-
all, taking into account the total number of risk factors
and stratifying them by age, a progressive increase with
age is observed, with an exponential increase in males,
which even doubles the risk from 75 years of age
(Fig. 3).
Analyzing the number of comorbidities in terms of
age, we note that less than 40 % of 18–25 year-old pa-
tients years showed any known risk factor, whereas after
age 55 there is an identified risk factor in the 85.7 % of
cases (one risk factor in 23.8 %, two factors in 23.4 %,
three in 18.2 %, four in 11.2 %, five in 5.5 % and six in
2.3 %) (Fig. 4). The association of comorbidities showed
no significant differences regarding sex in any age group.
Discussion
Our findings, based on the largest primary care popula-
tion database in Spain, indicate a high incidence of CAP
in primary care adults in Spain that is strongly associ-
ated with a high prevalence of multiple lifestyle risk fac-
tors and comorbidities. If we do not implement
appropriate interventions, the currently high and in-
creasing prevalence of these associated risk factors will
likely lead to an even higher incidence of CAP in the
aging population of Spain.
The global incidence of CAP in adults calculated in
this study (4.63/1000 person-years) is coherent with the
estimates from other Spanish studies, which range from
1.6 to 9 episodes per 1000 person-years [7]. According
to these results, the percentage of CAP is higher in
Spain compared to other European countries. As sug-
gested by other publications, this may be associated with
intrinsic differences in the structure of the health system
and other factors such as heterogeneity in the entry cri-
teria, or the possibility of care in the emergency unit,
among others [13]. Furthermore, our results confirm the
previous observations of higher incidence rates associ-
ated with men and older ages [14–16].
We found the highest burden of disease associated
with metabolic disease, cardiovascular disease and dia-
betes. These findings are consistent with pooled data
from observational studies which demonstrated that
patients with other medical conditions such as chronic
respiratory diseases, cardiovascular diseases, cerebrovas-
cular diseases, dementia and diabetes mellitus were the
most frequently observed comorbidities associated with
CAP [10, 11, 16]. Up to two-thirds of patients had a
chronic respiratory disease and almost half had a
chronic cardiovascular disease, highlighting the need for
appropriate management of these patients to reduce
their risk of CAP.
Lifestyle factors such as smoking, high alcohol intake
or being underweight have been associated with an in-
creased risk of CAP [10, 11, 16], which is consistent with
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Characteristics of the cohort
Pneumonia Type
Pneumonia (unspecified) 57.9 % (16.462) 53.7 % (557) 57.6 % (2.799) 59.3 % (3.297) 60.2 % (3.645) 56.9 % (4.262) 55.7 % (1.902)
Bacterial pneumonia 27.6 % (7.849) 21.2 % (220) 25.9 % (1.261) 26.7 % (1.486) 27.5 % (1.664) 29.7 % (2.226) 29.0 % (992)
Atypical pneumonia 3.5 % (999) 4.4 % (46) 5.2 % (251) 4.8 % (267) 3.7 % (222) 2.2 % (164) 1.4 % (49)
Viral pneumonia 2.8 % (801) 3.4 % (35) 3.8 % (183) 3.9 % (216) 2.8 % (171) 1.9 % (140) 1.6 % (56)
Complicated pneumonia 6.1 % (1.727) 17.1 % (177) 7.1 % (345) 4.7 % (263) 5.2 % (312) 6.1 % (456) 5.1 % (174)
Aspirative pneumonia 1.9 % (551) 0.3 % (3) 0.4 % (20) 0.5 % (26) 0.6 % (39) 3.0 % (224) 7.0 % (239)
Nosocomial pneumonia 0.1 % (24) 0.0 % (0) 0.0 % (2) 0.0 % (2) 0.1 % (4) 0.2 % (12) 0.1 % (4)
Gender
Female 48.3 % (13.716) 41.4 % (430) 49.6 % (2.411) 50.2 % (2.790) 48.7 % (2.949) 42.8 % (3.203) 56.6 % (1.933)
Male 51.7 % (14.697) 58.6 % (608) 50.4 % (2.450) 49.8 % (2.767) 51.3 % (3.108) 57.2 % (4.281) 43.4 % (1.483)
Risk factors
Alcoholism 2.5 % (700) 0.0 % (0) 0.8 % (39) 3.6 % (199) 4.2 % (256) 2.5 % (185) 0.6 % (21)
Tobacco 13.0 % (3.702) 8.0 % (83) 13.5 % (656) 20.9 % (1.163) 18.3 % (1.106) 8.3 % (621) 2.1 % (73)
Anemia 12.3 % (3.501) 5.7 % (59) 7.1 % (346) 9.0 % (498) 7.7 % (469) 16.7 % (1.253) 25.6 % (876)
Asthma 6.5 % (1.833) 7.8 % (81) 4.9 % (237) 5.0 % (277) 6.1 % (367) 8.2 % (615) 7.5 % (256)
Bronchitis 2.1 % (591) 0.2 % (2) 0.4 % (20) 0.9 % (51) 2.3 % (138) 3.5 % (265) 3.4 % (115)
COPD 10.8 % (3.055) 0.2 % (2) 0.2 % (9) 3.1 % (173) 11.7 % (709) 21.5 % (1.612) 16.1 % (550)
Low weight 2.9 % (828) 3.6 % (37) 2.5 % (121) 2.4 % (136) 2.4 % (148) 3.6 % (272) 3.3 % (114)
Cardiovascular disease 17.8 % (5.071) 0.5 % (5) 1.7 % (82) 4.3 % (238) 15.5 % (936) 33.0 % (2.469) 39.3 % (1.341)
Cerebrovascular disease 7.8 % (2.221) 0.1 % (1) 0.2 % (12) 0.9 % (48) 4.6 % (281) 14.4 % (1.077) 23.5 % (802)
Bipolar syndrome 0.2 % (63) 0.1 % (1) 0.2 % (8) 0.3 % (17) 0.3 % (16) 0.2 % (17) 0.1 % (4)
Dementia 4.3 % (1.233) 0.0 % (0) 0.0 % (1) 0.0 % (2) 0.9 % (54) 7.2 % (539) 18.6 % (637)
Psychiatric syndrome 0.2 % (71) 0.3 % (3) 0.1 % (4) 0.3 % (15) 0.3 % (16) 0.2 % (15) 0.5 % (18)
Depression 14.8 % (4.197) 2.1 % (22) 6.6 % (323) 12.0 % (667) 17.0 % (1.030) 19.4 % (1.452) 20.6 % (703)
Diabetes 15.5 % (4.415) 0.8 % (8) 1.5 % (75) 5.7 % (314) 17.9 % (1.082) 28.9 % (2.165) 22.6 % (771)
Metabolic disease 27.4 % (7.780) 1.7 % (18) 5.9 % (287) 17.7 % (986) 40.4 % (2.445) 41.5 % (3.106) 27.5 % (938)
Dysphagia 1.5 % (425) 0.4 % (4) 0.6 % (30) 0.6 % (36) 1.5 % (88) 2.0 % (153) 3.3 % (114)
Neurologic disease 1.3 % (362) 0.5 % (5) 0.5 % (22) 0.9 % (52) 1.7 % (100) 1.6 % (117) 1.9 % (66)
Parkinson 1.6 % (447) 0.0 % (0) 0.0 % (0) 0.1 % (3) 0.5 % (33) 3.4 % (258) 4.5 % (153)
Epilepsy 1.9 % (535) 2.0 % (21) 1.6 % (80) 1.7 % (93) 1.9 % (118) 2.0 % (149) 2.2 % (74)
Hepatic disease 1.7 % (472) 0.2 % (2) 0.5 % (23) 1.9 % (107) 2.7 % (165) 2.1 % (155) 0.6 % (20)
Chronic renal disease 0.2 % (44) 0.0 % (0) 0.0 % (0) 0.0 % (1) 0.1 % (6) 0.3 % (21) 0.5 % (16)
Rheumatologic disease 4.7 % (1.335) 0.6 % (6) 0.7 % (35) 1.9 % (104) 4.3 % (261) 7.8 % (582) 10.2 % (347)
HIV 1.0 % (295) 0.2 % (2) 1.4 % (70) 3.5 % (196) 0.4 % (23) 0.1 % (4) 0.0 % (0)
Poor dental hygiene 11.8 % (3.359) 9.1 % (94) 10.0 % (485) 11.5 % (639) 14.3 % (865) 13.6 % (1.021) 7.5 % (255)
Low social status 1.5 % (426) 0.8 % (8) 0.9 % (42) 1.1 % (63) 0.9 % (52) 2.0 % (147) 3.3 % (114)
Pneumococcal vaccination 0.1 % (18) 0.4 % (4) 0.1 % (5) 0.1 % (3) 0.0 % (2) 0.0 % (3) 0.0 % (1)
a Frequencies for categorical variables, number of patients between parenthesis
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our findings. Smoking and excessive alcohol consump-
tion are major health risks globally and are targets for
interventions to reduce the global burden of disease. En-
suring that patients make appropriate lifestyle changes
would help reduce the overall burden of CAP. Similarly,
being underweight may predispose patients to CAP due
to the consequences of undernutrition or underlying
conditions on immune function, so assessment of the
nutritional status of vulnerable patients might help iden-
tify those at increased risk of CAP.
Table 2 CAP incidence according to age and gender. Rates expressed per 1000 person-years
Male Female Total
Cases n p-y Rate Cases n p-y Rate Cases n p-y Rate
18–20 years 175 61,333 70,412.87 2.49 101 61,303 68,905.12 1.47 276 122,636 139,317.98 1.98
20–25 years 433 79,410 196,125.36 2.21 329 89,087 204,046.95 1.61 762 168,497 400,172.31 1.90
25–30 years 566 111,187 260,050.38 2.18 458 122,885 275,279.73 1.66 1024 234,072 535,330.11 1.91
30–35 years 818 134,560 332,654.60 2.46 796 140,318 343,610.41 2.32 1614 274,878 676,265.01 2.39
35–40 years 1070 123,355 336,083.56 3.18 1157 125,302 341,845.69 3.38 2227 248,657 677,929.25 3.29
40–45 years 1074 108,836 306,130.49 3.51 1060 110,765 309,832.41 3.42 2134 219,601 615,962.90 3.46
45–50 years 823 93,700 272,812.94 3.02 833 98,233 280,717.22 2.97 1656 191,933 553,530.15 2.99
50–55 years 874 81,114 239,243.53 3.65 903 88,311 256,471.30 3.52 1777 169,425 495,714.83 3.58
55–60 years 917 71,745 207,713.86 4.41 937 77,261 222,700.73 4.21 1854 149,006 430,414.59 4.31
60–65 years 1097 64,835 190,729.33 5.75 1080 71,241 207,353.03 5.21 2177 136,076 398,082.36 5.47
65–70 years 1098 48,791 155,627.10 7.06 935 54,759 172,088.42 5.43 2033 103,550 327,715.52 6.20
70–75 years 1214 41,283 116,993.45 10.38 890 51,806 143,029.88 6.22 2104 93,089 260,023.33 8.09
75–80 years 1604 36,855 109,640.33 14.63 1115 52,422 149,267.10 7.47 2719 89,277 258,907.43 10.50
80–85 years 1472 25,189 75,766.96 19.43 1204 43,904 125,031.08 9.63 2676 69,093 200,798.03 13.33
85–90 years 978 12,965 39,021.71 25.06 1081 28,978 83,030.03 13.02 2059 41,943 122,051.74 16.87
90–110 years 514 4952 13,917.42 36.93 873 15,937 44,495.90 19.62 1387 20,889 58,413.33 23.74
Total 14,727 1,100,110 2,922,923.88 5.04 13.752 1,232,512 3,227,704.99 4.26 28,479 2,332,622 6,150,628.88 4.63
Fig. 1 Distribution of the different lifestyle risk factors and comorbidities in patients seeking medical assistance because of pneumonia at primary
care, according to age. Legend:
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Overall, we observed substantially increased rates
of pneumonia among persons with >1 risk condition,
and disease rates were especially high among those
with ≥3 risk conditions. This is especially significant
when noting that risk factors tend to increase over
time: after age 55, we identified a risk factor in
85.7 % of cases, and risk even doubles from age 75.
This phenomenon of “risk stacking”— whereby risk
of disease increases with increasing numbers of risk
factors —has been noted for other diseases, for
example, osteoporotic hip fractures and cardiovascu-
lar events [17, 18].
One potential limitation of the study is the underesti-
mation of CAP incidence, as doubtful cases where there
was not sufficient information in the medical history, or
diagnosis of presumption was made without radiological
confirmation, were excluded. Another aspect to bear in
mind is that not all patients are initially diagnosed in
primary care. It is not uncommon for a person to go dir-
ectly to the hospital without going through the general
Fig. 2 Distribution of the different lifestyle risk factors and comorbidities in patients seeking medical assistance because of pneumonia at primary
care, according to gender. Legend:
Fig. 3 Global incidence of CAP stratified by age. Legend:
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practitioner, and such cases would not be initially re-
corded in our database. However, patients are commonly
referred to their general practitioner for follow-up, or
they inform the doctor about the episode suffered during
further consultation in the health center. Thus, even
though some cases may initially visit the emergency
room or be hospitalized, they can be classified as CAP,
provided that the doctor registers the episode in the pa-
tient’s medical history.
One of the strengths of BIFAP is that it is one of
the largest primary care databases available. It in-
cludes information provided by 2692 family physicians
and primary care pediatricians from the National
Health System, integrating information from 4,800,207
valid anonymized medical records for a total of
24,957,871 person-years of follow-up (5-year average
patient tracking); including: 76,561,939 records of
health problems, 414,852,056 medication records,
14,190,861 immunization records and 674,846,412
general records of patient data.
The organization of the Spanish public health sys-
tem sets the primary care as the main gateway to
other health services. Thus BIFAP includes a wealth
of information on when, how and why patients visit
primary care centers. Although the objective behind
the development of this database was to facilitate
pharmacoepidemiological studies, its potential is
greater. With appropriate methods and after overcom-
ing complex validation tests, BIFAP data can be used
to calculate incidence and prevalence of diseases from
thousands of patients, and to investigate risk factors
and associated prognostic factors [19, 20]. This re-
search is a population-based study, which could
determine accurately the incidence and prevalence of
risk factors of CAP in Spain, and demonstrates the
utility of BIFAP as a resource to estimate the preva-
lence and incidence of disease.
Conclusions
The incidence of CAP in primary care adults in Spain is
high, increases with age, and it is double in males as
compared to females over 75 years of age. The main risk
factors associated with CAP are metabolic disease, car-
diovascular disease, and diabetes, all of them increasing
nowadays, which could favor further increase in CAP in-
cidence. Additional studies assessing risk stratification
and a better understanding of the individual phenotypes
with the greatest risk of CAP could help the develop-
ment and implementation of the appropriate interven-
tions in order to reduce the risk of infection and burden
of CAP at the earliest level of medical care.
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